Sign In
Buy NRIX
$15.48
-0.89 (-5.44%)
At Close: Jun 03, 2026
Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET) Webcast Scheduled for Monday, December 12, 2022 at 8:30 PM CT (9:30 PM ET)
Wall Street Analysts Think Nurix Therapeutics, Inc. (NRIX) Could Surge 187%: Read This Before Placing a Bet
11:18am, Friday, 04'th Nov 2022
The consensus price target hints at an 187% upside potential for Nurix Therapeutics, Inc. (NRIX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e
Nurix Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 02'nd Nov 2022
SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hemat
Nurix: Down, But Not Out
01:43pm, Thursday, 27'th Oct 2022
There are four key data catalysts, one in each of Nurix's clinical candidates, arriving through end of the year. Nurix has a strong cash position that should be sufficient to fund operations through 2
The Top 5 Stocks Cathie Wood Bought and Sold This Week
05:10pm, Friday, 21'st Oct 2022
It has been another volatile week for Cathie Wood's flagship exchange-traded fund (ETF), the ARK Innovation ETF (NYSEARCA: ARKK ). Shares of ARKK recently hit a five-year low and 52-week low of $33.74
Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Lags Revenue Estimates
06:48pm, Thursday, 06'th Oct 2022
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 9.09% and 12.33%, respectively, for the quarter ended August 2022. Do the numbers hold clues to what lies ahead for the stoc
Nurix Therapeutics, Inc. (NRIX) Moves to Buy: Rationale Behind the Upgrade
01:33pm, Wednesday, 07'th Sep 2022
Nurix Therapeutics, Inc. (NRIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Nurix Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 31'st Aug 2022
SAN FRANCISCO, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sa
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Tops Revenue Estimates
06:33pm, Thursday, 07'th Jul 2022
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -1% and 13.36%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
06:47am, Tuesday, 31'st May 2022
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in t
Nurix Therapeutics Announces Participation in the 2022 RBC Capital Markets Global Healthcare Conference
04:02pm, Wednesday, 11'th May 2022
SAN FRANCISCO, May 11, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs, today announced th
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
06:49pm, Thursday, 07'th Apr 2022
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -6.74% and 9.68%, respectively, for the quarter ended February 2022. Do the numbers hold clues to what lies ahead for the st
Nurix Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Wednesday, 09'th Mar 2022
SAN FRANCISCO, March 09, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. S
SAN FRANCISCO, March 08, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that preclinica
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
09:01pm, Thursday, 10'th Feb 2022 GlobeNewswire
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurixs president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 PM ET.
